A medication producing 24% weight loss means nothing if patients cannot tolerate it long enough to reach those results
The fundamentals matter regardless of medication: Calorie deficit through proper nutrition High protein intake (0.7-1g per pound daily minimum) Resistance training 2-4x weekly Adequate sleep and stress management Sustainable lifestyle changes Medications like retatrutide can be powerful tools, but they work best when combined with the basics
Over 80% of people in the survey agreed that using a weight care medication made them more aware of what they were eating, and had made lasting changes to their physical activity as a result of being on the medication
Standard semaglutide pen needles range from 4 to 6 millimeters in length, which is sufficient to penetrate skin and reach the subcutaneous layer in most patients
But when it reaches the market, here's what to expect based on the current GLP-1 insurance landscape: If Approved for Type 2 Diabetes Most commercial insurance plans will cover it, especially if it demonstrates A1C reduction comparable to or exceeding tirzepatide Prior authorization will likely be required Step therapy (try metformin first, then other agents) is standard Copays with manufacturer savings: potentially $25$50/month If Approved for Obesity/Weight Management Coverage remains highly variable, and many plans still exclude weight management medications Medicare Part D: Congress has been debating coverage of anti-obesity medications, but it remains excluded as of early 2026 Self-insured employers increasingly adding GLP-1 coverage, but it's employer-specific Expect significant prior authorization requirements (BMI thresholds, failed diet attempts) The practical reality: even when retatrutide is approved, many people will face the same insurance barriers that currently exist for Wegovy and Zepbound
If not, skip it and resume your normal schedule
